Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
NXT15906F6 (TamaFlex) is a proprietary botanical combination consisting of standardized extracts from *Tamarindus indica* (tamarind) seeds and *Curcuma longa* (turmeric) rhizomes. It is developed as a synergistic formulation to support joint health and mitigate symptoms of osteoarthritis. Clinical studies have demonstrated that NXT15906F6 significantly reduces knee joint pain and improves musculoskeletal function and joint motility, with effects observed as early as five days after initiation. Its mechanism of action involves anti-inflammatory activity, evidenced by the reduction of systemic inflammatory markers like high-sensitivity C-reactive protein (hs-CRP), and chondroprotective effects, indicated by the reduction of the cartilage degradation marker C-terminal telopeptide of type II collagen (uCTX-II). It is primarily marketed as a dietary supplement for joint comfort and mobility.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on NXT15906F6.